Factory Price? Brexpiprazole CAS 913611-97-9 CAS NO.913611-97-9

Hubei Langyou International Trading Co., Ltd is a renowned pharmaceutical manufacturer. We specializing in the production of research and development of pharmaceutical intermediates, this kind of products with high quality price concessions, welcomed the new and old customers advisory purchase, companies invest large fund and brain research fine chemical r&d department,biochemical,  pharmaceutical and intermediate products to meet the demand of the market. High level research team,advanced equipment and good scientific atmosphere ensure the quality .

1.Reasonable and competitive price. Provide the best and professional service.Provide the best and professional service is our purpose.

2. Reliable shipping way.Door to door service, guarantee 100% delivery for you.

We have our own shipping agent in each country,we have special lines to your country, you no need do anything.

Will finish all the customs clearance at our side, customers are without any customs issues,door to door delivery.

3.To below countries, we are very  familiar and regular.

UK,USA,Canada,Russia,Ukraine,Kazakhstan,Belarus,Germany,Poland,Sweden,the Netherlands, Australia,Spain,Mexico,Poland  and so on. All are without problems.

Brexpiprazole

CAS: 913611-97-9

MF: C25H27N3O2S

MW: 433.57

EINECS: 811-628-7

Melting point 179 - 181oC

Boiling point 675.2±55.0 °C(Predicted)

density 1.245±0.06 g/cm3(Predicted)

storage temp. Refrigerator

solubility Dichloromethane (Slightly), Chloroform (Slightly), Methanol (Slightly)

pka 11.22±0.70(Predicted)

form Solid

color White to Off-White

Uses Brexpiprazole is a kind of atypical antipsychotic. It is a dopamine D2 receptor partial agonist. As a novel serotonin-dopamine activity modulator, it can be used for the treatment of schizophrenia, and for the adjunctive treatment for depression. It can also provide efficacy and tolerability over established adjunctive treatments formajor depressive disorder(MDD).Recent study has also suggested it can ameliorate PCP-induced cognitive deficits in mice via 5-HT1A receptors.

Mode of action Brexpiprazole's suggested mechanism of action is based on its impact on dopamine and serotonin receptors. As a serotonin-dopamine activity modulator (SDAM), it acts as a novel partial agonist for D2 dopamine and serotonin 1A receptors while effectively blocking the serotonin 2A receptors, as well as noradrenergic alpha 1B and 2C receptors.